Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris

被引:146
|
作者
Chams-Davatchi, Cheyda
Esmaili, Nafiseh
Daneshpazhooh, Maryam
Valikhani, Mahin
Balighi, Kamran
Hallaji, Zahra
Barzegari, Masoumeh
Akhyani, Maryam
Ghodsi, S. Zahra
Seirafi, Hassan
Tabrizi, Mohammad-Javad Nazemi
Mortazavi, Hossein
Mirshams-Shahshahani, Mostafa
机构
[1] Univ Tehran Med Sci, Razi Hosp, Dept Dermatol, Tehran 11996, Iran
[2] Univ Tehran Med Sci, Razi Hosp, Dept Dermatol, Pemphigus Res Unit, Tehran, Iran
关键词
D O I
10.1016/j.jaad.2007.05.024
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Pemphigus is a severe autoimmune blistering disease affecting the skin and mucosa. Mortality is high in the absence of treatment. Nowadays, treatment is based mainly on corticosteroids and cytotoxic drugs; however, because of the rarity of the disease worldwide, there is not yet a standard treatment based on randomized controlled trials, and the treatment used is based mainly on the experience of experts. Objective: The aim of this study was to compare the efficacy and safety of 4 treatment regimens for pemphigus vulgaris: prednisolone alone, prednisolone plus azathioprine, prednisolone plus mycophenolate mofetil, and prednisolone plus intravenous cyclophosphamide pulse therapy. Methods: One hundred twenty new cases of pemphigus vulgaris were enrolled. These patients were randomly allocated into 1 of 4 treatment groups (each comprising 30 patients) and received prednisolone (P), prednisolone and azathioprine (P/A), prednisolone and mycophenolate mofetil (P/MM), and prednisolone and intravenous cyclophosphamide pulse therapy (P/PC). They were followed up for I year at the Pemphigus Research Unit. Results: In groups P, P/A, P/MM, and P/PC, 23 (76.5%), 24 (80%), 21 (70%), and 22 (73.3%) of the patients, respectively, followed the regimen for the full 1-year period. The mean total dose of prednisolone administered in groups P, P/A, P/MM, and P/PC was 11631 mg (standard deviation [SD] = 7742), 7712 mg (SD = 955), 9798 mg (SD = 3995), and 8276 mg (SD = 810), respectively. The mean total dose of prednisolone in group P (prednisolone alone) was 11,631 mg, The mean total dose of prednisolone in the 3 cytotoxic groups was 8652 mg. By using analysis of variance, the difference was statistically significant (P =.047). in the cytotoxic groups, there was a significant difference between the P/A and P/MM groups (P =.007), but not between P/A and P/PC (P =.971), and P/MM and P/PC (P =.670). Side effects were not significantly different among the 4 groups. Limitations: Larger sample sizes and blind design are suggested for future studies. Conclusion. The efficacy of prednisolone is enhanced when it is combined with a cytotoxic drug. The most efficacious cytotoxic drug to reduce steroid was found to be azathioprine, followed by cyclophosphamide (pulse therapy), and mycoplienolate mofetil.
引用
收藏
页码:622 / 628
页数:7
相关论文
共 50 条
  • [42] Efficacy and Safety of Mizoribine for the Treatment of Refractory Nephrotic Syndrome: Protocol for a Multicenter, Controlled, Open-label, Randomized Controlled Trial
    Dong, Zheyi
    Zhou, Jianhui
    Xu, Zhonggao
    Ni, Zhaohui
    He, Yani
    Lin, Hongli
    Jiang, Gengru
    Sun, Xuefeng
    Zhang, Li
    Chen, Xiangmei
    JMIR RESEARCH PROTOCOLS, 2023, 12
  • [43] Treatment of pulmonary mucormycosis with adjunctive nebulized amphotericin B (MUCONAB trial): Results of an open-label randomized controlled trial
    Muthu, Valliappan
    Gogineni, Ratnakara Rao
    Agarwal, Ritesh
    Prasad, Kuruswamy Thurai
    Sehgal, Inderpaul Singh
    Dhooria, Sahajal
    Aggarwal, Ashutosh N.
    Rudramurthy, Shivaprakash Mandya
    Singh, Harkant
    Garg, Mandeep
    Chakrabarti, Arunaloke
    MYCOSES, 2023, 66 (08) : 688 - 696
  • [44] Atomoxetine and methylphenidate treatment in children with ADHD: A prospective, randomized, open-label trial
    Kratochvil, CJ
    Heiligenstein, JH
    Dittmann, R
    Spencer, TJ
    Biederman, J
    Wernicke, J
    Newcorn, JH
    Casat, C
    Milton, D
    Michelson, D
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2002, 41 (07): : 776 - 784
  • [45] Open trial of mycophenolate mofetil in the treatment of resistant pemphigus vulgaris
    Chams-Davatchi, C
    Azar, RN
    Daneshpazooh, M
    Valikhani, M
    Hallaji, Z
    Barzegari, M
    Firouz, AR
    Zakeri, M
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2002, 129 (01): : 23 - 25
  • [46] Open-label placebo treatment to improve relaxation training effects in healthy psychology students: a randomized controlled trial
    Anne Schienle
    Isabella Unger
    Scientific Reports, 11
  • [47] Complete withdrawal is the most feasible treatment for medication-overuse headache: A randomized controlled open-label trial
    Engelstoft, Ida Maria Storm
    Carlsen, Louise Ninett
    Munksgaard, Signe Bruun
    Nielsen, Mia
    Jensen, Rigmor Hojland
    Bendtsen, Lars
    EUROPEAN JOURNAL OF PAIN, 2019, 23 (06) : 1162 - 1170
  • [48] Adjunctive vitamin D for the treatment of active juvenile idiopathic arthritis: An open-label, prospective, randomized controlled trial
    Tang, Tao
    Zhang, Yu
    Luo, Chong
    Liu, Mingyue
    Xu, Li
    Tang, Xuemei
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2019, 18 (06) : 4921 - 4926
  • [49] Open-Label Placebo for the Treatment of Cancer-Related Fatigue in Patients with Advanced Cancer: A Randomized Controlled Trial
    Yennurajalingam, Sriram
    Azhar, Ahsan
    Lu, Zhanni
    Rodriguez, Ashley J.
    Arechiga, Adrienne B.
    Guerra-Sanchez, Maria
    Stanton, Penny
    Andersen, Clark R.
    Urbauer, Diana L.
    Bruera, Eduardo
    ONCOLOGIST, 2022, 27 (12): : 1081 - 1089
  • [50] Treatment of asymptomatic vaginal candidiasis in pregnancy to prevent preterm birth: an open-label pilot randomized controlled trial
    Christine L Roberts
    Kristen Rickard
    George Kotsiou
    Jonathan M Morris
    BMC Pregnancy and Childbirth, 11